Jitsubo CO., LTD. announced  the signing of an exclusive manufacturing license agreement with Novo Nordisk A/S（2880 Bagsvaerd, Denmark, hereinafter “Novo Nordisk”）for Novo Nordisk to use and have manufacturing rights to Jitsubo’s proprietary peptide manufacturing technology, Molecular Hiving^TM, for synthesis of peptides in the field of obesity, diabetes, and the related therapeutic areas.

News Release PDF

CPHI Japan2023

We are pleased to announce that we will be exhibiting together with SPERA PHARMA,  Inc. and SPERA NEXUS, Inc. of the Astena Holdings.

◆Date : 19th to 21th, April 2023

◆Place : Tokyo Big Sight Exhibition Center, Tokyo, Japan

◆Booth :5H-12

For further details, please visit website.

https://www.cphi.com/japan/